Previous close | 1,733.50 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 8,173,218 |
Market cap | 71.814B |
Beta (5Y monthly) | 0.27 |
PE ratio (TTM) | 16.16 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.60 (3.41%) |
Ex-dividend date | 16 May 2024 |
1y target est | N/A |
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections
PHILADELPHIA, March 16, 2024--RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
PHILADELPHIA, March 07, 2024--GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise